References
- KondoSアルベカシンの開発とメチシリン耐性黄色ブドウ球菌による酵素的修飾をうけない新規誘導体の合成. [Development of arbekacin and synthesis of new derivatives stable to enzymatic modifications by methicillin-resistant Staphylococcus aureus]Jpn J Antibiot1994476561574 Japanese8072163
- TanakaNMatsunagaKHirataAMatsuhisaYNishimuraTMechanism of action of Habekacin, a novel amino acid containing aminoglycoside antibioticAntimicrob Agents Chemother19832457978026362557
- WatanabeAYanagiharaKMatsumotoTNationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2009: general view of the pathogens’ antibacterial susceptibilityJ Infect Chemother201218560962022766652
- YamaguchiKIshiiYIwataMMeropenem を含む各種注射用抗菌薬に対する2006年臨床分離株の感受性サーベイランス. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006]Jpn J Antibiot2007606344377 Japanese18447206
- NishinoTSakuraiMIn vitro activity of everninomicin (SCH 27899)Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and ChemotherapyOctober 17–20, 1993Louisiana, New Orleans Abstract No 462
- OkamotoRIyobeSMitsuhashiSHBKの細菌学的検討 [Antibacterial activity of HBK]Chemother198634110 Japanese
- KazunoYTsunetaSTamraABactriological evaluation of a new aminoglycoside antibiotic, HBKChemother1986346171
- MatsuhashiYYamamotoHメチシリン・セフェム耐性黄色ブドウ球菌の産生するアミノ配糖体系抗生物質不活化酵素に関する研究 [The enzymatic mechanisms of resistant to aminoglycoside antibiotics in methicillin-cephem-resistant Staphylococcus aureus]Jpn J Antibiot1988415523529 Japanese3216474
- NikiYHanakiHYagisawaMJapanese Society of Chemotherapy. The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibilityJ Infect Chemother200814427929018709531
- NikiYHanakiHMatsumotoTNationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens’ antibacterial susceptibilityJ Infect Chemother200915315616719554400
- NikiYHanakiHMatsumotoTNationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2008: general view of the pathogens’ antibacterial susceptibilityJ Infect Chemother201117451052321409533
- TakesueYWatanabeAHanakiHNationwide surveillance of antimicrobial susceptibility patterns of pathogens isolated from surgical site infections (SSI) in JapanJ Infect Chemother201218681682623143280
- MikuniyaTKatoYMuto-KobayashiYPrevalence of drug resistant gene and changes in susceptibility of methicillin-resistant Staphylococcus aureus strains isolated from 1990 to 2006 in Japan to antimicrobial agentsJpn J Chemother20096153740
- WatanabeTOhashiKMatsuiKKubotaTComparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicilin-resistant Staphylococcus aureusJ Antimicrob Chemother19973944714769145819
- FlandroisJPFardelGCarretGEarly stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureusAntimicrob Agents Chemother19883244544572837137
- AsserayNJacquelineCLe MabecqueVActivity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacyAntimicrob Agents Chemother200549285785915673789
- TakahashiTMatsumotoFMiyazakiSComparison of in vitro antibacterial activity of arbekacin, vancomycin and teicoplanin against methicillin-resistant Staphylococcus aureusJpn J Chemother1999472103107
- KurazonoMYamadaKHiraiYIdaTInoueMMRSA の疫学動向と各種抗菌薬の抗菌活性について. [Epidemiological survey of drug resistance of methicillin–resistant Staphylococcus aureus isolated in Japan in 2000]Jpn J Chemother2002508494499 Japanese
- MiyataAAraakeMOgawaHHanakiHHiramatsuKMRSAの Toxic shock syndrome toxin-1(TSST-1)産生に及ぼす arbekacinの作用. [Effect of Arbekacin of the production of toxic shock syndrome toxin 1 by methicillin-resistant Staphylococcus aureus]Jpn J Antibiotics2001547372381 Japanese11560056
- AraokaHBabaMTatedaKIn vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in JapanJpn J Infect Dis2012651848722274165
- KataokaHIdaTIshiiYAnalysis of the influence of drug resistance factors on the efficacy of combinations of antibiotics for multidrug-resistant Pseudomonas aeruginosa isolated from hospitals located in the suburbs of Kanto area, JapanJournal of Global Antimicrobial Resistance2013129196
- ZaporMJBarberMSummersAIn vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical CenterAntimicrob Agents Chemother20105473015301720404121
- Overview of Habekacin Injectable Solution (additional pediatric indication)In-house document of Meiji Seika Kaisha, Ltd
- AikawaNKohnoSKakuMWatanabeAYamaguchiKTanigawaraYAn open clinical study of arbekacin 200 mg qd in patients infected with methicillin-resistant Staphylococcus aureus (MRSA) – A clinical pharmacology studyJpn J Chemother2008563299312
- SunakawaKHoriS健康成人男性におけるアルベカシン硫酸塩400mg又は600mg投与時の安全性及び薬物動態. [Safety and pharmacokinetics of 400 and 600 mg arbekacin sulfate to healthy male volunteers]Jpn J Antibiotics201366297109 Japanese23951728
- SuzukiKTanikawaKMatsuzakiTPharmacokinetics and dosing of arbekacin in preterm and term newborn infantsPediatr Int200345217517912709144
- KinoshitaD新しい推奨ピーク値を目標とした新生児に対するアルベカシン1日1回投与法の検討. [Evaluation of once a day of arbekacin administration to neonates as a new object of peak concentration]Kansenshogaku Zasshi2010846727733 Japanese21226325
- FunatsuYHasegawaNNamkoongHPenetration of arbekacin sulfate to the lung tissueProceedings of the 52nd interscience conference on antimicrobial agents and chemotherapySeptember 9–12, 2012San Francisco Abstract No 2068
- CarcasAJGarcia-SatueJLZapaterPFrias-IniestaJTobramycin penetration into epithelial lining fluid of patients with pneumoniaClin Pharmacol Ther199965324525010096256
- KimuraTSunakawaKMatsuuraNKuboHShimadaSYagoKPopulation pharmacokinetics of arbekacin, vancomycin, and panipenem in neonatesAntimicrob. Agents Chemother20044841159116715047516
- KogaKKusawakeYItoYSugiokaNShibataNTakadaKEnhancing mechanism of Labrasol on intestinal membrane permeability of the hydrophilic drug gentamicin sulfateEur J Pharm Biopharm2006641829116750354
- BlaserJRiederHLLuthyRInterface-area-to-volume ratio of interstitial fluid humans determined by pharmacokinetic analysis of netilmicin in small and large skin blistersAntimicrob Agents Chemother19913558378391854165
- DeeTHKozinFGentamicin and tobramycin penetration into synovial fluidAntimicrob Agents Chemother1977124548549921252
- ThysJPSerruvs-SchoutensERocmansPHerchuelzAVanderlindenMPYourassowskyEAmikacin concentration in uninfected post thoracotomy pleural fluid and in serum after intravenous and intrapleural injectionChest19848545025056705579
- KozakAJGerdingDNPetersonLRHallWHGentamicin intravenous infusion rate: effect on interstitial fluid concentrationAntimicrob Agents Chemother1977125606608921257
- ChisholmGDWaterworthPMCalnanJSGarrodLPConcentration of antibacterial agents in interstitial tissue fluidBr Med J1973158535695734694402
- LorentzenHKallehaveFKolmosHJKniggeUBulowJGottrupFGentamicin concentrations in human subcutaneous tissueAntimicrob Agents Chemoter199640817851789
- RosinEEbertSUphoffTSEvansMHSchultz-DarkenNJPenetration of antibiotics into the surgical wound in a canine modelAntimicrob Agents Chemoter1989335700704
- HayashiMOoiKYamadaアルベカシン硫酸塩静注後の滲出液中濃度と血中濃度を測定した4症例. [Arbekacin sulfate concentration in peripheral lymph and in serum after intravenous injection: report of four cases]Jpn J Antibiot2012653207215 Japanese23173295
- OkadaKKimuraTMikamoHClinical practice guidelines for therapeutic drug monitoring of arbekacin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug MonitoringJ Infect Chemother20142011524486168
- ShimizuAMaebashiKNiidaMS03044. Pharmacokinetic-pharmacodynamic (PK-PD) study of arbekacin using mouse MRSA thigh infection modelIn-house document of Meiji Seika Kaisha, Ltd2003
- MattieHCraigWAPechereJCDetermination of efficacy and toxicity of aminoglycosidesJ Antimicrob Chemother19892432812932681115
- CraigWAPharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and menClin Infect Dis19982611129455502
- SatoRTanigawaraYKakuMAikawaNShimizuKPharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother200650113763376917065622
- NegitaKYamashitaMKubotaTStudy on therapeutic drug monitoring of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus and its efficacyJpn J Pharm Health Care Sci2001272123131
- NambaraMIkeueHKawasakiETomiokaSShimokawaFTanabeKEffectiveness and adverse reactions between once daily and every other day administration of arbekacin sulfateJpn J Ther Drug Monit2003203241248
- KobayashiMSaikyoASomaKYagoKSunakawaKPharmacokinetic and pharmacodynamics (PK-PD) analysis to determine the optimal method of arbekacin administrationJpn J Chemother20065411824
- TanikazeNKomatsuMShimakawaKYamamotoIメチシリン耐性黄色ブドウ球菌肺炎に対する硫酸アルベカシン治療における PK/PD 解析の臨床的有用性. [Study of clinical significance of PK/PD (pharmacokinetics/pharmacodynamics) parameters after administering arbekacin to patients with pulmonary methicillin-resistant Staphylococcus aureus infection]Jpn J Chemother2004529469473 Japanese
- HwangJHLeeJHMoonMKKimJSWonKSLeeCSThe usefulness of arbekacin compared to vancomycinEur J Clin Microbiol Infect Dis20123171663166622124537
- HwangJHLeeJHMoonMKKimJSWonKSLeeCSThe efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue mrsa infection: preliminary studyInfect Chemother2013451626824265951
- MatsumotoTHanakiHKimuraTClinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional studyJ Infect Chemother201319112813723263188
- KawanoHTanigawaraYPostmarketing surveillance review of arbekacin sulfate in patients with therapeutic drug monitoringJpn J Ther Drug Monit20102725571
- YamamotoYIzumikawaKHashiguchiKThe efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infectionJ Infect Chemother201218224124622398881
- KimuraTSunakawaKTotsukaKDose finding study on arbekacin sulfate for appropriate peak levelsJpn J Chemother2011596597604
- AraokaHBabaMTakagiSMonobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multi-drug-resistant Pseudomonas aeruginosa screened using a ‘break-point checkerboard plate’Scand J Infect Dis201042323123320001223
- Mingeot-LeclercqMPTulkensPMAminoglycosides: nephrotoxicityAntimicrob Agents Chemother19994351003101210223907
- SwanSKAminoglycoside nephrotoxicitySemin Nephrol199717127339000547
- GiulianoRAVerpootenGAVerbistLWedeenRPDe BroeMEIn vivo uptake kinetics of aminoglycosides in the kidney cortex of ratsJ Pharmacol Exp Ther198623624704753944768
- RougierFClaudeDMaurinMAminoglycoside nephrotoxicity: modeling, simulation, and controlAntimicrob Agents Chemother20034731010101612604535
- ChanbersHEChemotherapy of microbial diseases antimicrobial agents: the aminoglycosidesHardmanJGLimbirdLEGoodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th editionNew YorkMcGraw-Hill200112191238
- HuyPTBMannelCMenlemansAKinetics of aminoglycoside antibiotics in perilymph in animalsLernerSAMartzGJHawkinsJEAminoglycoside OtotoxicityLittle, Brown and Company19818197
- TulkensPMClerckx-BraunFDonnezJSafety and efficacy of aminoglycosides once-a-day: experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory diseaseJ Drug Dev19881Suppl 37182
- TotsukaKShimizuKMitomiNNiizatoTAraakeMArbekacinの1日1回投与法の検討 基礎的検討及びヒトにおける体内動態. [Evaluation of once-daily administration of arbekacin]Jpn J Antibiotics1994476676692 Japanese8072176
- BatesDEAminoglycoside ototoxicityDrugs Today (Barc)200339427728512743643
- BarclayMLKirkpatrickCMBeggEJOnce daily aminoglycoside therapy – Is it less toxic than multiple daily doses and how should it be monitored?Clin Pharmacokinet1999362899810092956
- YamasobaTInner ear disorders and mitochondrial DNA mutationPractica Oto-Rhino-Laryngologica20111048533540
- HamasakiKRandoRRSpecific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafnessBiochemistry1997364012323123289315872